Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-18.62/-6.35
|
|
Enterprise Value
26.59M
|
| Balance Sheet |
|
Book Value Per Share
-6.04
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
398.00K
|
|
Operating Revenue Per Share
--
|
|
Industry Comparison
|
||||||||||||||||
|
||||||||||||||||
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases. |

0.66 
